• Partial BACE Inhibition and Synaptic Transmission

  2026-09-14

  Satir et al. tested whether moderate BACE inhibition could lower amyloid-β production without disrupting neuronal communication. Their data indicate that reductions of less than 50% in secreted Aβ were compatible with preserved synaptic transmission in primary rat cortical cultures, whereas stronger inhibition reduced both measures.

• EdU Imaging Kits (HF594) and the PNI Decision Point

  2026-09-14

  A mechanistic and translational guide to using EdU-based S-phase measurements to interpret Schwann-cell dedifferentiation, tumor–nerve crosstalk, and therapeutic response in pancreatic ductal adenocarcinoma.

• FAK Inhibitor 14: From Mechanism to Translation

  2026-09-13

  A translational perspective on using FAK Inhibitor 14 to interrogate the PARP1/FAK/COL5A1 axis, EMT, migration, and cholesterol-adapted ovarian cancer models while maintaining rigorous experimental boundaries.

• Sildenafil Citrate: A Proteoform-Aware Assay Guide

  2026-09-12

  Sildenafil Citrate is a cGMP-specific phosphodiesterase type 5 inhibitor with broad value in vascular signaling research. This guide translates native proteoform findings into practical assay design, selectivity controls, and interpretable cGMP and ERK readouts.

• α-Linolenic Acid Research Workflows

  2026-09-11

  Build reproducible ALA experiments spanning lipid flux, cardiovascular phenotypes, inflammation, and cancer biology. This practical guide combines solvent handling, time-course design, pathway-aware controls, and a cautious translation of new arachidonic acid immune findings.

• Developmental SSRI Exposure and Mu Opioid Signaling

  2026-09-11

  Cambre’s 2026 Columbia University dissertation shows that developmental exposure to selective serotonin reuptake inhibitors produces persistent, motivation-specific reward deficits in adolescent and adult mice. Progressive-ratio performance improved after mu opioid receptor antagonism or nucleus accumbens MOR knockdown, whereas further SSRI treatment and the MOR agonist tianeptine were ineffective, pointing to a dissociation between serotonergic history and opioid control of effortful behavior.

• Capsazepine: From TRPV1 Blockade to Translation

  2026-09-10

  A translational strategy for using Capsazepine to separate TRPV1 biology from calcium-current, TRPM8, nociceptive, and exploratory apoptosis effects while improving mechanistic confidence in pain models.

• Cabazitaxel (XRP6258): Resistant Model Guide

  2026-09-10

  Cabazitaxel (XRP6258, SKU B2157) is a semi-synthetic taxane derivative for studying microtubule dynamics disruption and antiproliferative responses, including P-glycoprotein-expressing and taxane-resistant cancer cell models. It is intended for controlled DMSO- or ethanol-based workflows, not water-only assays, and prepared solutions should be used promptly rather than stored long term.

• N-MYC–eIF4G1 Axis in inv(16) AML

  2026-09-09

  Peramangalam and colleagues identify an N-MYC enhancer and the translation-initiation factor eIF4G1 as a survival pathway in inv(16) acute myeloid leukemia. Their integrated use of transcriptomic analysis, leukemia models, enhancer studies, and functional perturbation supports the N-MYC/eIF4G1 axis as a mechanistic framework for studying leukemic maintenance, while also defining important limits for therapeutic interpretation.

• Fenipentol Workflows for Secretion Research

  2026-09-09

  Fenipentol provides a defined small-molecule tool for testing pancreatic, hepatobiliary, and intestinal secretion phenotypes rather than relying only on complex Chuanxiong extracts. This guide connects historical secretion data with modern metabolomics, ESR1-oriented hypotheses, practical dosing workflows, and troubleshooting strategies.

• Upd2 Directs Disciplined Tracheal Stem Cell Migration

  2026-09-08

  Dong et al. show that the Drosophila fat body controls the anterior-to-posterior migration of tracheal progenitors through the cytokine Upd2 and tracheal JAK/STAT signaling. The study connects inter-organ cytokine transport, planar cell polarity, and vesicular trafficking to the maintenance of coordinated stem cell movement.

• (-)-JQ1: BET Control for BRD4 Assays

  2026-09-08

  Use (-)-JQ1 as a matched inactive control to separate BRD4-dependent biology from solvent, handling, and nonspecific cytotoxicity. Its value is greatest in HPV-associated cancer models, where transcriptional responses to BET inhibition can vary substantially between cell lines.

• Maraviroc (UK-427857): CCR5 Mechanism and Uses

  2026-09-07

  Maraviroc (UK-427857) is a selective CCR5 antagonist for R5-tropic HIV-1 entry studies and receptor-signaling research. Its nanomolar cellular activity supports HIV-1 entry inhibition assays, while evidence for neuroinflammation modulation and ischemic-stroke applications remains investigational.

• N-MYC–eIF4G1 Survival Axis in inv(16) AML

  2026-09-07

  Peramangalam et al. identify an N-MYC–eIF4G1 pathway that supports survival and maintenance of inv(16) acute myeloid leukemia. The study combines transcriptomic analysis, enhancer interrogation, genetic perturbation, primary leukemia models, and patient-derived xenografts to connect MYCN regulation with a previously unrecognized leukemic dependency.

• FPS-ZM1: A Practical RAGE Inhibitor Workflow

  2026-09-05

  FPS-ZM1 enables controlled testing of RAGE-dependent amyloid beta signaling, neuronal stress, and neuroinflammation without treating broad metabolic effects as proof of RAGE causality. This workflow connects brain-focused assays with emerging RAGE/POMC research while emphasizing formulation, controls, and translational limits.

8471 records 1/565 page Next 12345 下5页 Last page